Dr. Harry Ridgway is CSO and founder of THERAmolecular. He is an Adjunct Professor (Victoria University, Institute for Sustainable Industry and Liveable Cities), entrepreneur and independent research scientist. Working at the crossroads of computational drug discovery and molecular modeling of functional nano-porous materials, Dr. Ridgway supports organizations around the globe in achieving their research visions. Since 2016, he has been engaged in computational drug design research for corporate and academic clients. He has expertise in state-of-the-art commercial and open-source chem/bioinformatics and drug-discovery platforms, including Molsoft’s internal coordinate mechanics (ICM) algorithms. Additionally, he has extensive experience in the coding and application of classical mechanics and quantum-level calculations for modeling chemical reactions and for carrying out molecular dynamics (MD) simulations of polymer networks and drug-receptor complexes. Dr. Ridgway holds undergraduate and doctoral degrees in microbiology (chemistry minor) from San Diego State University and UC San Diego’s Scripps Institute of Oceanography. He conducted postdoctoral studies in molecular biology and environmental microbiology at the San Diego and Irvine campuses of the University of California. With a robust and diverse record of academic achievement and publications, Dr. Ridgway pioneered studies of bacterial adhesion and biofilm interactions with synthetic permselective desalination membrane materials. In 2002 he was the 9th recipient of the prestigious Clarke Water Prize for contributions made in water science and technology. His current research at THERAmolecular is focused on the design of safe and effective drugs targeting hypertension, addiction, depression and related neurological disorders, such as Parkinson's Disease.